Adiponectin concentrations increase during acute FFA elevation in humans treated with rosiglitazone.
The adipocytokine adiponectin is released by adipocytes upon activation of the peroxisome proliferator-activated receptor gamma (PPAR gamma). PPAR gamma has binding sites for thiazolidinediones and free fatty acids (FFAs). To evaluate if adiponectin serum concentrations are synergistically regulated by FFAs and thiazolidinediones IN VIVO plasma FFAs were acutely elevated in healthy subjects pre-treated with rosiglitazone or placebo. Sixteen healthy male subjects (23-37 years) were included in this double-blind, randomized, placebo-controlled parallel-group study. Rosiglitazone 8 mg or placebo was administered daily for 21 days. On the last day plasma FFA concentrations were increased by an intravenous triglyceride/heparin infusion. Blood for determination of adiponectin, C-reactive protein (CRP), leptin, resistin, FFAs, glucose, and insulin was drawn at baseline and on day 21 before and after 5 hours of triglyceride/heparin infusion. Adiponectin concentrations increased and FFA levels decreased in subjects receiving rosiglitazone (all p<0.05 VS. baseline). Lipid infusion significantly increased FFA plasma concentrations, with an attenuated elevation in rosiglitazone-treated subjects. However, adiponectin concentrations were only increased in subjects on rosiglitazone (p=0.018 VS. before lipid infusion), but not in controls. Leptin increased during lipid infusion in subjects receiving placebo but not in those on rosiglitazone. CRP and resistin were not affected by rosiglitazone or FFAs. The acute increase in circulating adiponectin concentrations during acutely elevated FFA depends on PPAR gamma activation in healthy subjects.
Krzyzanowska
K
K
Department of Internal Medicine I, Rudolfstiftung Hospital, Vienna, Austria. katarzyna.krzyzanowska@wienkav.at
Mittermayer
F
F
Krugluger
W
W
Roden
M
M
Schernthaner
G
G
Wolzt
M
M
D052242:Adiponectin / Q000097:blood*; D000328:Adult; D001786:Blood Glucose / Q000032:analysis / Q000187:drug effects; D002097:C-Reactive Protein / Q000032:analysis; D004311:Double-Blind Method; D005230:Fatty Acids, Nonesterified / Q000097:blood / Q000378:metabolism*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology; D007260:Infusion Pumps; D020738:Leptin / Q000097:blood; D008055:Lipids / Q000008:administration & dosage; D008297:Male; D010919:Placebos; D052243:Resistin / Q000097:blood; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000008:administration & dosage / Q000494:pharmacology*; D013997:Time Factors
D052242:Adiponectin; D001786:Blood Glucose; D005230:Fatty Acids, Nonesterified; D007004:Hypoglycemic Agents; D020738:Leptin; D008055:Lipids; D010919:Placebos; C499624:RETN protein, human; D052243:Resistin; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D002097:C-Reactive Protein